Mass General Brigham
Health Plan

Lucemyra (lofexidine)
Effective 07/01/2023

Plan	☒ MassHealth UPPL ☐Commercial/Exchange	**Program Type**	☒ Prior Authorization ☐ Quantity Limit ☐ Step Therapy
Benefit	☒ Pharmacy Benefit ☐ Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	**Specialty Medications**		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview
Lofexidine is a new central α-2 adrenergic agonist that was approved by the FDA to lessen the opioid withdrawal symptoms in adults who are undergoing abrupt opioid discontinuation.

Coverage Guidelines
Authorization may be reviewed on a case by case basis for members who are new to the plan currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.
OR
Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Diagnosis of opioid withdrawal symptoms
2. Member is ≥ 18 years of age
3. Physician attestation of inadequate response, adverse reaction, or contraindication to oral clonidine
4. Requested dose is ≤ 0.72 mg four times daily
5. Requested duration is ≤ 14 days

<u>Continuation of Therapy</u>
Reauthorization will require physician documentation for a separate detoxification event within the same year.

Limitations

1. Initial approvals will be granted for a total duration of 14 days
2. Reauthorizations will be granted for a total duration of 14 days

a. Recertifications within the same year will be granted for another 14-day duration
b. If request documents that member has been started and stabilized on Lucemyra®, continuation of therapy will be allowed to complete a total duration not to exceed 14 days.

3. Dosing information:

Lucemyra® (lofexidine) Tablet: 0.18 mg	Three tablets four times daily for first five to seven days (depending on opioid withdrawal symptoms); Not to exceed (NTE) four tablets in one dose or 16 tablets for total daily dose Total treatment duration NTE 14 days

References

1. Lucemyra® [package insert]. Louisville (KY): US WorldMeds, LLC; 2018 May
2. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-367. doi: 10.1097/ADM.0000000000000166
3. Akhurst JS. Lofexidine in opiate withdrawal: a safety and usage survey. Pharmacoepidemiol Drug Saf. 2000;9(1):43-47
4. Sevarino K. Medically supervised opioid withdrawal during treatment for addiction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed December 21, 2017

Review History

06/14/2023 - Created for P&T in order to match MH UPPL. Effective 7/1/23.